Fluticasone propionate as a potential treatment for COVID-19
- PMID: 35535815
- DOI: 10.1358/dot.2022.58.5.3381591
Fluticasone propionate as a potential treatment for COVID-19
Abstract
Outpatient treatment options for mild to moderate COVID-19 are severely limited. While many therapeutic options have been proposed, very few have demonstrated the appropriate safety and efficacy to warrant approval by national or international regulatory bodies. Monoclonal antibodies have been shown to decrease hospitalization in high-risk patients, but use remains limited due to challenges associated with both production and administration, and other treatment options are urgently needed. The anti-inflammatory drug fluticasone propionate has recently emerged as a potential outpatient treatment option, especially for those with newly diagnosed disease. This manuscript reviews what is known about fluticasone and looks ahead to examine how the drug may be used in the future to address the COVID-19 pandemic.
Keywords: COVID-19; Drug repurposing; Fluticasone propionate; Glucocorticoid receptor agonists; Inhaled corticosteroids; SARS-CoV-2 infection.
Copyright 2022 Clarivate.
Similar articles
-
Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma.J Allergy Clin Immunol. 1998 Jul;102(1):32-8. doi: 10.1016/s0091-6749(98)70052-1. J Allergy Clin Immunol. 1998. PMID: 9679845 Clinical Trial.
-
Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.Ann Allergy Asthma Immunol. 1999 Mar;82(3):273-80. doi: 10.1016/S1081-1206(10)62608-7. Ann Allergy Asthma Immunol. 1999. PMID: 10094218 Clinical Trial.
-
Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects.Thorax. 2001 Mar;56(3):186-91. doi: 10.1136/thorax.56.3.186. Thorax. 2001. PMID: 11182010 Free PMC article. Clinical Trial.
-
Safety of inhaled fluticasone propionate therapy for pediatric asthma - a systematic review.Curr Drug Saf. 2013 Jul;8(3):186-94. doi: 10.2174/15748863113089990038. Curr Drug Saf. 2013. PMID: 23859431 Review.
-
Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.Drugs. 1999 May;57(5):769-803. doi: 10.2165/00003495-199957050-00016. Drugs. 1999. PMID: 10353302 Review.
Cited by
-
Outcomes and risk factors with COVID-19 or influenza in hospitalized asthma patients.Respir Res. 2022 Dec 13;23(1):342. doi: 10.1186/s12931-022-02265-6. Respir Res. 2022. PMID: 36514068 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous